Rafael Holdings, Inc.'s subsidiary, Cyclo Therapeutics, is advancing its pivotal phase 3 TransportNPC study, which evaluates the intravenous treatment Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The study is set to continue following a positive review by an independent Data Monitoring Committee $(DMC.AU)$ of safety and efficacy data at the 48-week interim mark. The FDA has approved the statistical analysis plan for this study. The investigational candidate has demonstrated a safety profile consistent with earlier phase 1 and 2 studies. This study is considered the most comprehensive of its kind for NPC, both in terms of its scale and the breadth of clinical outcomes assessed.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。